Over-the-counter sales of statins and other drugs for asymptomatic conditions

New England Journal of Medicine

Volumn 358, Issue 25, 2008, Pages 2728-2732

  Tinetti, Mary E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NON PRESCRIPTION DRUG;

DRUG MARKETING; DRUG SAFETY; HYPERCHOLESTEROLEMIA; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SELF CARE; SELF MEDICATION;

EID: 45549106184     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsb0801202     Document Type: Article

References (22)

1. NDA 21-213: Mevacor daily tablets nonprescription lovastatin 20 mg): Advisory Committee background package available for public disclosure without redaction. West Point, PA: Merck Research Laboratories, November 8, 2007. (Accessed May 30, 2008, at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4331b1-02-Merck.pdf.)
2. Briefing document: Joint Session of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee, December 13, 2007. Rockville, MD: Food and Drug Administration. (Accessed May 30, 2008, at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4331b1-01-FDA. pdf)
3. Nag SS, Pearson TA, Ma L, et al. Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease. Am J Cardiol 2005;95:862-4.
4. Summary minutes of the Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee, December 13, 2007. Rockville, MD: Food and Drug Administration. (Accessed May 30, 2008, at http://www.fda.gov/ohrms/dockets/ac/07/minutes/2007- 4331m1-Final.pdf.)
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
6. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
7. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO Study. Cardiovasc Drugs Ther 2005;19:403-14.
8. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002;58:1333-7.
9. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57:525-8.
10. Bang OY, Saver JL, Liebeskind DS, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007;68:737-42. [Erratum, Neurology 2007;68:1547.]
11. Amarenco P, Bogousslavsky J, Callahan A III, et al. Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
12. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. [Erratum, Lancet 2005;366:1358.]
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143-421.
14. Brass EP, Allen SE, Melin JM. Potential impact on cardiovascular public health of over-the-counter statin availability. Am J Cardiol 2006;97:851-6.
15. Hu L. FDA briefing document: SELECT study NDA 21-213 proposing over-the-counter Mevacor (lovastatin) 20 mg. (Accessed May 30, 2008, at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4331b1-01-FDA.pdf.)
16. Melin JM, Struble WE, Tipping RW, et al. A Consumer Use Study of Over-The-Counter Lovastatin (CUSTOM). Am J Cardiol 2004;94:1243-8.
17. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007;357:673-81.
18. Gahart MT, Duhamel LM, Dievler A, Price R. Examining the FDA's oversight of direct-to-consumer advertising. Health Aff (Millwood) 2003;Suppl Web Exclusives:W3-120-W3-123.
19. Food and Drug Administration Amendments Act of 2007. (Accessed May 30, 2008, at http://www.fda.gov/oc/initiatives/fdaaa/PL110-85.pdf.)
20. Non-Prescription Drug Modernization Act of 2007 fact sheet. (Accessed May 30, 2008, at http://oversight.house.gov/documents/20071106174240.pdf.)
21. McClellan M. Drug safety reform at the FDA - pendulum swing or systematic improvement? N Engl J Med 2007;356:1700-2.
22. Psaty BM, Burke SP. Protecting the health of the public - Institute of Medicine recommendations on drug safety. N Engl J Med 2006;355:1753-5.